DK118655B - Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater. - Google Patents

Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater.

Info

Publication number
DK118655B
DK118655B DK433463AA DK433463A DK118655B DK 118655 B DK118655 B DK 118655B DK 433463A A DK433463A A DK 433463AA DK 433463 A DK433463 A DK 433463A DK 118655 B DK118655 B DK 118655B
Authority
DK
Denmark
Prior art keywords
aminoalkoxyphenylalkene
derivatives
preparation
analogous process
analogous
Prior art date
Application number
DK433463AA
Other languages
Danish (da)
English (en)
Inventor
M Harper
D Richardson
A Walpole
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26260578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK118655(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB34989/62A external-priority patent/GB1013907A/en
Application filed by Ici Ltd filed Critical Ici Ltd
Publication of DK118655B publication Critical patent/DK118655B/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/64Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring
    • C07C37/66Preparation of O-metal compounds with O-metal group bound to a carbon atom belonging to a six-membered aromatic ring by conversion of hydroxy groups to O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK433463AA 1962-09-13 1963-09-13 Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater. DK118655B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB34989/62A GB1013907A (en) 1962-09-13 1962-09-13 Alkene derivatives
GB30755/65A GB1064629A (en) 1962-09-13 1965-07-20 Alkene derivatives

Publications (1)

Publication Number Publication Date
DK118655B true DK118655B (da) 1970-09-21

Family

ID=26260578

Family Applications (3)

Application Number Title Priority Date Filing Date
DK433463AA DK118655B (da) 1962-09-13 1963-09-13 Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater.
DK432067AA DK117953B (da) 1962-09-13 1967-08-25 Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater.
DK355571AA DK127777B (da) 1962-09-13 1971-07-19 p-(Aminoalkoksy)fenyl-stilbenderivater til anvendelse som svangerskabsforebyggende midler.

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK432067AA DK117953B (da) 1962-09-13 1967-08-25 Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater.
DK355571AA DK127777B (da) 1962-09-13 1971-07-19 p-(Aminoalkoksy)fenyl-stilbenderivater til anvendelse som svangerskabsforebyggende midler.

Country Status (8)

Country Link
US (1) US4536516A (US06171609-20010109-C00001.png)
BE (2) BE678807A (US06171609-20010109-C00001.png)
BR (2) BR6352734D0 (US06171609-20010109-C00001.png)
CH (3) CH446289A (US06171609-20010109-C00001.png)
DE (1) DE1568834A1 (US06171609-20010109-C00001.png)
DK (3) DK118655B (US06171609-20010109-C00001.png)
FR (1) FR1502607A (US06171609-20010109-C00001.png)
GB (1) GB1064629A (US06171609-20010109-C00001.png)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (US06171609-20010109-C00001.png) * 1962-09-13
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity
US4206234A (en) * 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
HU178253B (en) * 1979-08-15 1982-04-28 Gyogyszerkutato Intezet Process for preparing 1,1,2-triphenyl-propane and -propane derivatives
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
DE3462398D1 (en) * 1983-05-24 1987-04-02 Bristol Myers Co Process for the conversion of the e isomer of 1,2-diphenyl-1-(4-(2-dimethylaminoethoxy)-phenyl)-1-butene to tamoxifen hcl
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US4806685A (en) * 1985-08-05 1989-02-21 Gyogyszerkutato Inteezet/Pharmaceutical Research Institute 1,1,2-triphenylpropane and -propene derivatives
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
CA1289570C (en) * 1986-06-16 1991-09-24 Tetsuji Asao 1,1,2-triaryl-1-alkene derivatives
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
DE3736682A1 (de) * 1987-10-29 1989-05-11 Klinge Co Chem Pharm Fab Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5204337A (en) * 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5446203A (en) * 1992-08-25 1995-08-29 New York University Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5354861A (en) * 1992-11-04 1994-10-11 National University Of Singapore 2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
IL110052A (en) * 1993-06-24 2001-04-30 Lilly Co Eli Pharmaceutical preparations containing derivatives of benzothiophene used as hypoglycemic compounds
US5451590A (en) * 1993-12-21 1995-09-19 Eli Lilly & Co. Methods of inhibiting sexual precocity
US5462950A (en) * 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
GB9326255D0 (en) * 1993-12-23 1994-02-23 Roussel Lab Ltd Medical device for the prevention and treatment of cancer
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
TW398975B (en) 1994-07-22 2000-07-21 Lilly Co Eli Pharmaceutical composition for inhibiting bone loss
ATE377418T1 (de) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
EP0883587A1 (en) 1996-01-20 1998-12-16 Bradford University Tamoxifen and analogues thereof
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6083990A (en) * 1997-04-02 2000-07-04 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
CA2280181A1 (en) * 1997-02-09 1998-08-13 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
JP2001513105A (ja) * 1997-02-27 2001-08-28 フアルマシア・アンド・アツプジヨン・カンパニー 塩酸イリノテカン誘発性下痢軽減治療薬としてのタモキシフェン
GB9715479D0 (en) * 1997-07-23 1997-10-01 Univ Bradford Tamoxifen and analogues thereof
WO1999008682A1 (en) 1997-08-15 1999-02-25 Duke University A method of preventing or treating estrogen-dependent diseases and disorders
UA66370C2 (en) 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
AU2003254261B2 (en) * 2002-07-30 2008-04-17 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
CA2539361A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP1729793B1 (en) 2004-03-02 2015-07-22 Acceleron Pharma Inc. Alk7 and myostatin inhibitors for muscle wasting disorders
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
KR20070084455A (ko) * 2004-11-23 2007-08-24 워너-램버트 캄파니 엘엘씨 지질혈증 치료용 hmg co-a 환원효소 억제제로서의7-(2h-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
CA2594477C (en) 2005-01-21 2016-07-12 Astex Therapeutics Limited Pharmaceutical compounds
ZA200800907B (en) 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
RU2480207C2 (ru) 2006-05-22 2013-04-27 Хормос Медикал Лтд. Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы
EP2034984A4 (en) 2006-06-02 2013-03-06 Pear Tree Women S Health Care PROCESS FOR TREATING ATROPHIC VAGINITIS
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
US8501713B2 (en) 2007-08-03 2013-08-06 Summit Corporation Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CN102940619A (zh) 2007-10-16 2013-02-27 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
CA2861377A1 (en) 2012-01-31 2013-08-08 Novartis Ag Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
CA2865234A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
EP3296300B1 (en) 2012-03-05 2019-08-07 Xavier University Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer
CN103992234B (zh) * 2014-06-11 2016-05-18 扬子江药业集团江苏海慈生物药业有限公司 一种枸橼酸他莫昔芬e异构体的制备方法
CN108348605B (zh) 2015-11-10 2023-06-09 帕拉卡林治疗公司 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌
WO2017120204A2 (en) 2016-01-05 2017-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
WO2017136342A1 (en) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
AU2017312499B2 (en) 2016-08-19 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
CA3090807A1 (en) 2018-02-21 2019-08-29 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
CN114514021A (zh) * 2019-06-10 2022-05-17 爱荷华大学研究基金会 用于治疗非酒精性脂肪性肝病、免疫缺陷、男性不育症和血管疾病的swell1调节剂
CN114133334A (zh) * 2021-11-09 2022-03-04 北京京丰制药(山东)有限公司 枸橼酸他莫昔芬的工业化制备工艺
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
EP4311546A1 (en) 2022-07-26 2024-01-31 Dynacure Combination therapy for myopathies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1013907A (en) * 1962-09-13 1965-12-22 Ici Ltd Alkene derivatives
BE637389A (US06171609-20010109-C00001.png) * 1962-09-13
GB1029221A (en) * 1963-09-02 1966-05-11 Ici Ltd Triarylalkane derivatives
US3288806A (en) * 1964-03-23 1966-11-29 Parke Davis & Co Alpha-(aminoethoxyphenyl)-alpha-alkylstilbenes
GB1099093A (en) * 1965-09-03 1968-01-17 Ici Ltd Alkene derivatives
GB1560274A (en) * 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity

Also Published As

Publication number Publication date
DK127777B (da) 1974-01-07
BE637389A (US06171609-20010109-C00001.png)
CH441286A (de) 1967-08-15
CH446289A (de) 1967-11-15
US4536516A (en) 1985-08-20
BR6678265D0 (pt) 1973-09-18
BE678807A (US06171609-20010109-C00001.png) 1966-09-30
FR1502607A (fr) 1967-11-24
DE1568834A1 (de) 1970-11-26
DE1468088A1 (de) 1969-07-31
CH538447A (de) 1973-06-30
BR6352734D0 (pt) 1973-09-18
GB1064629A (en) 1967-04-05
DK117953B (da) 1970-06-22

Similar Documents

Publication Publication Date Title
DK117953B (da) Analogifremgangsmåde til fremstilling af p-aminoalkoxyphenylalkenderivater.
DK115403B (da) Fremgangsmåde til fremstilling af (3-amino-pyrazinoyl)-guanidiner.
DK120490B (da) Fremgangsmåde til fremstilling af thiaxanthenderivater.
DK104675C (da) Fremgangsmåde til fremstilling af 3-hydroxy-N-nitro-picolinamid.
DK115325B (da) Fremgangsmåde til fremstilling af fenylalkylsulfamider.
DK103476C (da) Fremgangsmåde til fremstilling af 2-oxa-3-oxo-steroider.
DK103512C (da) Fremgangsmåde til fremstilling af 3-nitroso-2-oxazolidon.
DK108915C (da) Fremgangsmåde til fremstilling af 21-acyloxy-acetyloxy-corticosteroider.
DK106337C (da) Fremgangsmåde til fremstilling af 3α-phenylgranatanderivater.
DK102920C (da) Fremgangsmåde til fremstilling af 1-cyancolchicinderivater.
DK104680C (da) Fremgangsmåde til fremstilling af derivater af 6-methyl-8-aminomethyl-ergolin I.
DK104063C (da) Fremgangsmåde til fremstilling af 4-hydroxy-5-halogenpyrimidiner.
DK113647B (da) Fremgangsmåde til fremstilling af 2-sulfanilamido-5-metoxypyrimidin.
DK115620B (da) Fremgangsmåde til fremstilling af 17α-klorætynyl-17βalkoksysteroider.
DK104065C (da) Fremgangsmåde til fremstilling af 3-phenylgranaten-(2)-derivater.
DK122391B (da) Analogifremgangsmåde til fremstilling af 2-hydroxybenzopyridocolinderivater.
DK105532C (da) Fremgangsmåde til fremstilling af 1-hydroxymethyl-14-aminocolchicinderivater.
DK105766C (da) Fremgangsmåde til fremstilling af 1-hydroxymethyldesacetylaminothiocolchicinderivater.
DK102746C (da) Fremgangsmåde til fremstilling af 3β-fenylgranatanderivater.
DK104105C (da) Fremgangsmåde til fremstilling af 2-alkoxycycloheptimidazol-derivater.
DK104413C (da) Fremgangsmåde til fremstilling af 1-hydroxymethylcolchicinderivater.
DK104941C (da) Fremgangsmåde til fremstilling af 1-hydroxymethylthiocolchicinderivater.
DK115555B (da) Fremgangsmåde til fremstilling af nitrofurfurylidenderivater.
DK103833C (da) Fremgangsmåde til fremstilling af desacetylamino-N-methylcolchiceinamid.
DK108624C (da) Fremgangsmåde til fremstilling af 1α-metylcorticoider.